TLDR Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
A 35-year-old female patient with Palmoplantar Pustulosis (PPP) developed Alopecia Areata (AA), a rare side effect, after treatment with secukinumab, a drug that targets interleukin-17 (IL-17). After discontinuing secukinumab and starting treatment with tofacitinib, both her AA and PPP significantly improved. The study suggests that tofacitinib could be a potential treatment for AA induced by biologics during PPP treatment. However, more research with larger sample sizes is needed to confirm these findings.
28 citations,
March 2018 in “Archives of Dermatological Research” 
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
61 citations,
June 2010 in “Journal of the European Academy of Dermatology and Venereology” Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
1 citations,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
24 citations,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
16 citations,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
16 citations,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
